- Home
- MRNA vs GMAB Comparison
MRNA vs GMAB Comparison
Compare MRNA & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | GMAB |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | 3029 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 16.7B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRNA | GMAB |
|---|---|---|
| Price | $49.11 | $27.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $33.00 | ★ $39.81 |
| AVG Volume (30 Days) | ★ 7.1M | 1.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $8.59 | $17.80 |
| Revenue Next Year | $16.72 | $14.86 |
| P/E Ratio | ★ N/A | $1.90 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $17.24 |
| 52 Week High | $59.55 | $35.43 |
Technical Indicators
Market Signals| Indicator | MRNA | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 50.95 |
| Support Level | $48.09 | $24.95 |
| Resistance Level | $54.94 | $33.75 |
| Average True Range (ATR) | 2.63 | 0.56 |
| MACD | -0.77 | 0.32 |
| Stochastic Oscillator | 17.40 | 92.91 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.